EGFR+ Lung Cancer
Latest News
Advertisement
Latest Videos
Advertisement
More News
Final data from 2 phase I expansion studies confirmed the efficacy of frontline osimertinib (Tagrisso) in patients with <em>EGFR</em>-positive non­–small cell lung cancer, investigators reported during the 2019 European Lung Cancer Congress.
Alexander Drilon, MD, discussed updated findings with larotrectinib in <em>NTRK</em> fusion–positive tumors and entrectinib in <em>ROS1</em> fusion–positive NSCLC.<br />
The approval for pembrolizumab (Keytruda) has been expanded to include the frontline treatment of patients with stage III non–small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression level of ≥1% and do not harbor <em>EGFR</em> or <em>ALK</em> aberrations.
Combining osimertinib with the MET inhibitor savolitinib demonstrated encouraging antitumor activity and an acceptable safety profile in patients with <em>EGFR</em>-mutant, <em>MET</em>-amplified non–small cell lung cancer who previously received EGFR TKIs, suggesting the regimen could be successful in overcoming <em>MET</em>-driven resistance.
Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Naiyer A. Rizvi, MD, explained, in a presentation at the European Society of Medical Oncology 2019 International Congress on Targeted Anticancer Therapies, that plasma assays for determining TMB are becoming more diagnostically relevant.
A look back at all the FDA news that happened in March 2019, including several new approvals, a clinical hold, an orphan drug designation, and more.
In findings presented during the 2019 AACR Annual Meeting, safety and efficacy was seen with CAR T cells targeting mesothelin-expressing tumors in a preliminary clinical evaluation in patients with malignant pleural disease.
Lurbinectedin (PM1183) monotherapy induced responses in patients with relapsed small cell lung cancer, achieving the primary endpoint of overall response rate in a single-arm phase II trial, according to an announcement from PharmaMar, the company developing lurbinectedin.
The efficacy of osimertinib does not significantly vary according to the body size variables of patients with T790M-positive non–small cell lung cancer who progress on prior EGFR tyrosine kinase inhibitors, according to findings from a new study published in <em>Thoracic Cancer</em>.<br />
The FDA has approved the combination of atezolizumab plus carboplatin and etoposide as a first-line treatment for patients with extensive-stage small cell lung cancer.
Based on 2 case scenarios, H. Jack West, MD, discusses treatment options and the data that support these options for the management of squamous and nonsquamous non–small cell lung cancer.
The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Kartik Konduri, MD, recently discussed the treatment considerations and decisions he makes when treating patients with non–small cell lung cancer.
Robert L. Ferris, MD, PhD, Co-Physician Editor in Chief, <em>Targeted Therapies in Oncology</em>,<em> </em>discusses<em> </em>the<em> </em>evolving<em> </em>role of immunotherapy in melanoma and non–small cell lung cancer, where by it is now the dominant therapeutic approach in these diseases in progressively earlier lines of therapy.
Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Progression-free survival, the primary endpoint of the RELAY trial, was significantly improved with frontline ramucirumab in combination with erlotinib compared to placebo plus erlotinib in patients with metastatic <em>EGFR</em>-mutant non–small cell lung cancer.
Due to an active research landscape, the National Comprehensive Cancer Network Guidelines for non–small cell lung cancer have had 3 recent updates that include numerous clinically relevant recommendations.
Edward B. Garon, MD, discusses the role of EGFR-targeted therapies in the treatment landscape of NSCLC.
A look back at all the FDA news in oncology from the month of February 2019, including several new approvals, priority review designations, and an orphan drug desgination.
Guardant360—a 73-gene next-generation sequencing panel—detected all of the guideline-recommended biomarkers in patients newly diagnosed with metastatic non–small cell lung cancer at a similar rate, but in a faster turnaround time than tissue genotyping, according to data from the NILE study.
Stage IIIB Unresectable NSCLC After Chemoradiotherapy
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
